Effect of algorithm aggressiveness on the performance of the Hypoglycemia-Hyperglycemia Minimizer (HHM) system

Journal of Diabetes Science and Technology

Volumn 8, Issue 4, 2014, Pages 685-690

  Finan, Daniel A ^a   McCann Jr , Thomas W ^a   Rhein, Kathleen ^a   Dassau, Eyal ^b,c   Breton, Marc D ^d   Patek, Stephen D ^d   Anhalt, Henry ^a   Kovatchev, Boris P ^d   Doyle III, Francis J ^b,c   Anderson, Stacey M ^e   Zisser, Howard ^b,c   Venugopalan, Ramakrishna ^a  

^a Animas Corporation   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SANSUM DIABETES RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Aggressiveness factor; Algorithm; Artificial pancreas; Closed loop; Tuning parameter

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADULT; ADVERSE EFFECTS; ALGORITHM; BLOOD; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; FEASIBILITY STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN INFUSION; MALE; METABOLISM; PATIENT SAFETY; STATISTICS AND NUMERICAL DATA;

ADULT; ALGORITHMS; BLOOD GLUCOSE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; FEASIBILITY STUDIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; PATIENT SAFETY;

EID: 84905924687     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296814534589     Document Type: Article

References (10)

1. Kowalski AJ. Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. Diabetes Technol Ther. 2009;11(suppl 1):S113-S119.
2. Breton M, Farret A, Bruttomesso D, et al. Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes. 2012;61(9):2230-2237.
3. Dassau E, Zisser H, Harvey RA, et al. Clinical evaluation of a personalized artificial pancreas. Diabetes Care. 2013;36(4):801-809.
4. Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet. 2010;375(9716):743-751.
5. Russell SJ, El-Khatib FH, Nathan DM, Magyar KL, Jiang J, Damiano ER. Blood glucose control in type 1 diabetes with bihormonal bionic endocrine pancreas. Diabetes Care. 2012;35(11):2148-2155.
6. Philip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med. 2013;368(9):824-833.
7. Kovatchev BP, Renard E, Cobelli C, et al. Feasibility of outpatient fully integrated closed-loop control: first studies of a wearable artificial pancreas. Diabetes Care. 2013;36(7): 1851-1858.
8. Finan DA, McCann TW Jr, Mackowiak L, et al. Closed-loop control performance of the Hypoglycemia-Hyperglycemia Minimizer (HHM) System in a feasibility study. J Diabetes Sci Technol. 2014;8(1):35-42.
9. Dassau E, Zisser H, Palerm CC, Buckingham BA, Jovanovic L, Doyle FJ III. Modular artificial beta-cell system: a prototype for clinical research. J Diabetes Sci Technol. 2008;2(5): 863-872.
10. U.S. Food and Drug Administration/Center for Devices and Radiological Health. The content of investigational device exemption (IDE) and premarket approval (PMA) applications for artificial pancreas device systems. 2012.